Molecular Therapy Nucleic Acids Impact Factor, Quartile, Indexing, Ranking

Molecular Therapy Nucleic Acids Impact Factor, Indexing, Ranking

Molecular Therapy Nucleic Acids (MrNA) is a scholarly journal dedicated to publishing research in the field of Pharmacology, Toxicology and Pharmaceutics, and Published by Cell Press. and its abbreviation is Mol Ther Nucleic Acids.


Molecular Therapy Nucleic Acids Aim and Scope

Molecular Therapy Nucleic Acids is an international, open-access journal publishing top-quality basic, translational, and clinical research in the broad fields of nucleic-acid-based therapeutics to treat and/or correct genetic and acquired disease. As an official journal of the American Society of Gene & Cell Therapy, Molecular Therapy Nucleic Acids builds upon the success of Molecular Therapy in publishing important peer-reviewed research, cutting-edge reviews, and commentaries targeted to advances in gene- and oligonucleotide-based therapies.

Subject areas include but are not limited to: development of therapeutics based on nucleic acids and their derivatives, vector development and design for the delivery of RNA-based therapeutics, applications of gene-modifying agents including triplex-forming oligonucleotides and enzymes such as Zn finger nucleases, pre-clinical target validation, safety/efficacy studies, and clinical trials.


Molecular Therapy Nucleic Acids Details


Journal title Molecular Therapy Nucleic Acids (MrNA)
Abbreviation Mol Ther Nucleic Acids
Online ISSN 2162-2531
Publisher Name Cell Press
Editor-in-chief Paloma H. Giangrande
Subject Category Pharmacology, Toxicology and Pharmaceutics
Access type Logo of open access journals Open Access
Acceptance rate 18.44%
Impact Factor 8.8
SJR 1.947
SNIP 1.318
Ranking 1569
CiteScore 15.6
H-Index 84
Quartile Q1
Review Time 4.41 weeks
Status 🟢 Active
Abstracting and Indexing
Impact Factor List 2024

Who we are? Clarification: Journals Insights - Your Open Access Ally
F T L W E